Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanSTU:L74 -5.06%50 PS Ratio is 11.76 as of Sep. 01, 2026, which is 0% above its 10-year median of 11.72. GuruFocus rates STU:L74 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks worse than 85.07% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, WuXi XDC Cayman's share price is €7.50.
WuXi XDC Cayman's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.64. Hence, WuXi XDC Cayman's PS Ratio for today is 11.76.
The historical rank and industry rank for WuXi XDC Cayman's PS Ratio or its related term are showing as below:
STU:L74'
s PS Ratio Range Over the Past 10 Years
Min: 6.73 Med: 11.72 Max: 35.57
Current: 12.31
During the past 6 years, WuXi XDC Cayman's highest PS Ratio was 35.57. The lowest was 6.73. And the median was 11.72.
STU:L74's PS Ratio is ranked worse than 85.07% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.66
vs STU:L74: 12.31
WuXi XDC Cayman Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of WuXi XDC Cayman was 47.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 74.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 119.50% per year.
During the past 6 years, WuXi XDC Cayman's highest 3-Year average Revenue per Share Growth Rate was 181.10% per year. The lowest was 74.10% per year. And the median was 118.30% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
WuXi XDC Cayman PS Ratio Related Terms
WuXi XDC Cayman PS Ratio Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, WuXi XDC Cayman's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's PS Ratio distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
WuXi XDC Cayman's Share Price of today is €7.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi XDC Cayman's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.64.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
WuXi XDC Cayman (STU:L74) has a PS Ratio of 11.76 as of Sep. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on WuXi XDC Cayman and its competitors. This is near median its historical median of 11.72. Over the past decade, WuXi XDC Cayman's PS Ratio has ranged from 6.73 to 35.57. According to the industry distribution chart, WuXi XDC Cayman ranks #171 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 85.1%.
Is WuXi XDC Cayman's PS Ratio too high?
WuXi XDC Cayman's current PS Ratio of 11.76 is near median its 10-year median of 11.72. Over the past 10 years, this metric has ranged from a low of 6.73 to a high of 35.57. The Medical Diagnostics & Research industry median PS Ratio is 2.66. WuXi XDC Cayman's value of 11.76 is 342.1% above this industry median. Based on the distribution chart, WuXi XDC Cayman ranks #171 out of 201 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #171 out of 201 companies for PS Ratio. This places WuXi XDC Cayman in the lower half of its industry. The industry median PS Ratio is 2.66. WuXi XDC Cayman's value of 11.76 is 342.1% above this benchmark. Historically, WuXi XDC Cayman's own PS Ratio has ranged from 6.73 to 35.57 over the past decade. While the company's 10-year median is 11.72 vs. the industry median of 2.66, WuXi XDC Cayman has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.66, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi XDC Cayman's current PS Ratio of 11.76 is 342.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on WuXi XDC Cayman and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current PS Ratio is 11.76, which is near median its own 10-year median of 11.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (STU:L74) has a current PS Ratio of 11.76. The current PS Ratio is 11.76, which is near median its 10-year median of 11.72 and 342.1% above the Medical Diagnostics & Research industry median of 2.66. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For WuXi XDC Cayman (STU:L74), the current PS Ratio is 11.76 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for STU:L74
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L74 has been successfully added to your 
